150 related articles for article (PubMed ID: 37731302)
1. A randomized trial to evaluate the preventive effect of lafutidine on chemotherapy-induced peripheral neuropathy in patients treated with carboplatin and paclitaxel for lung cancer.
Cho K; Saikawa H; Hashimoto T; Katagiri H; Owada Y; Yakuwa K; Fujimura I; Utsumi Y; Akiyama M; Nagashima H; Takahashi F; Maemondo M
Ann Palliat Med; 2023 Nov; 12(6):1136-1145. PubMed ID: 37731302
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx).
Cheng HL; Molassiotis A
Asia Pac J Clin Oncol; 2019 Feb; 15(1):56-62. PubMed ID: 29873180
[TBL] [Abstract][Full Text] [Related]
3. Cryocompression to Reduce Peripheral Neuropathy in Gynecologic Cancer: A Randomized Controlled Trial.
Anastasio MK; Unnithan S; Scott A; Hayes T; Shah S; Moss HA; Erkanli A; Havrilesky LJ
Obstet Gynecol; 2023 Dec; 142(6):1459-1467. PubMed ID: 37883997
[TBL] [Abstract][Full Text] [Related]
4. Performance of the FACT-GOG-Ntx to assess chemotherapy-induced peripheral neuropathy (CIPN) in pediatric high risk Hodgkin lymphoma: report from the Children's Oncology Group AHOD 1331 study.
Parsons SK; Rodday AM; Pei Q; Keller FG; Wu Y; Henderson TO; Cella D; Kelly KM; Castellino SM
J Patient Rep Outcomes; 2023 Nov; 7(1):113. PubMed ID: 37947987
[TBL] [Abstract][Full Text] [Related]
5. A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients.
Bao T; Seidman AD; Piulson L; Vertosick E; Chen X; Vickers AJ; Blinder VS; Zhi WI; Li Q; Vahdat LT; Dickler MN; Robson ME; Mao JJ
Eur J Cancer; 2018 Sep; 101():12-19. PubMed ID: 30007894
[TBL] [Abstract][Full Text] [Related]
6. Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study).
Kuroi K; Shimozuma K; Ohashi Y; Hisamatsu K; Masuda N; Takeuchi A; Aranishi T; Morita S; Ohsumi S; Hausheer FH
Support Care Cancer; 2009 Aug; 17(8):1071-80. PubMed ID: 19089463
[TBL] [Abstract][Full Text] [Related]
7. Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes.
Li T; Timmins HC; Trinh T; Mizrahi D; Harrison M; Horvath LG; Grimison P; Friedlander M; Kiernan MC; King MT; Rutherford C; Goldstein D; Park SB
J Natl Compr Canc Netw; 2023 Feb; 21(2):125-132.e3. PubMed ID: 36791763
[TBL] [Abstract][Full Text] [Related]
8. Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02.
Shimozuma K; Ohashi Y; Takeuchi A; Aranishi T; Morita S; Kuroi K; Ohsumi S; Makino H; Mukai H; Katsumata N; Sunada Y; Watanabe T; Hausheer FH
Support Care Cancer; 2009 Dec; 17(12):1483-91. PubMed ID: 19330359
[TBL] [Abstract][Full Text] [Related]
9. North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study.
Leal AD; Qin R; Atherton PJ; Haluska P; Behrens RJ; Tiber CH; Watanaboonyakhet P; Weiss M; Adams PT; Dockter TJ; Loprinzi CL;
Cancer; 2014 Jun; 120(12):1890-7. PubMed ID: 24619793
[TBL] [Abstract][Full Text] [Related]
10. The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: a prospective observational multicenter study protocol (IVY).
Tanioka H; Nagasaka T; Uno F; Inoue M; Okita H; Katata Y; Kanzaki H; Kuramochi H; Satake H; Shindo Y; Doi A; Nasu J; Yamashita H; Yamaguchi Y
BMC Cancer; 2019 Oct; 19(1):941. PubMed ID: 31604467
[TBL] [Abstract][Full Text] [Related]
11. Impact of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-Based Chemotherapy.
Hung HW; Liu CY; Chen HF; Chang CC; Chen SC
Int J Environ Res Public Health; 2021 May; 18(11):. PubMed ID: 34073174
[TBL] [Abstract][Full Text] [Related]
12. Supplement Use and Chemotherapy-Induced Peripheral Neuropathy in a Cooperative Group Trial (S0221): The DELCaP Study.
Zirpoli GR; McCann SE; Sucheston-Campbell LE; Hershman DL; Ciupak G; Davis W; Unger JM; Moore HCF; Stewart JA; Isaacs C; Hobday TJ; Salim M; Hortobagyi GN; Gralow JR; Budd GT; Albain KS; Ambrosone CB
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29546345
[TBL] [Abstract][Full Text] [Related]
13. Psychometric testing of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy.
Cheng HL; Lopez V; Lam SC; Leung AKT; Li YC; Wong KH; Au JSK; Sundar R; Chan A; De Ng TR; Suen LKP; Chan CW; Yorke J; Molassiotis A
Health Qual Life Outcomes; 2020 Jul; 18(1):246. PubMed ID: 32703223
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in platinum-sensitive recurrent ovarian, fallopian or primary peritoneal cancer: study protocol for a phase III, double-blind, randomized study.
Park SJ; Yim GW; Paik H; Lee N; Lee S; Lee M; Kim HS
J Gynecol Oncol; 2021 Sep; 32(5):e73. PubMed ID: 34132071
[TBL] [Abstract][Full Text] [Related]
15. Cryotherapy for the prevention of weekly paclitaxel-induced peripheral adverse events in breast cancer patients.
Shigematsu H; Hirata T; Nishina M; Yasui D; Ozaki S
Support Care Cancer; 2020 Oct; 28(10):5005-5011. PubMed ID: 32036471
[TBL] [Abstract][Full Text] [Related]
16. Incidence of chemotherapy-induced peripheral neuropathy within 12 weeks of starting neurotoxic chemotherapy for multiple myeloma or lymphoma: a prospective, single-center, observational study.
Ajewole VB; Cox JE; Swan JT; Chikermane SG; Lamoth B; Iso T; Okolo LO; Ford CL; Schneider AM; Hobaugh EC; Baker KR
Support Care Cancer; 2020 Apr; 28(4):1901-1912. PubMed ID: 31359183
[TBL] [Abstract][Full Text] [Related]
17. Prospective Evaluation of Health Care Provider and Patient Assessments in Chemotherapy-Induced Peripheral Neurotoxicity.
Alberti P; Bernasconi DP; Cornblath DR; Merkies ISJ; Park SB; Velasco R; Bruna J; Psimaras D; Koeppen S; Pace A; Dorsey SG; Argyriou AA; Kalofonos HP; Briani C; Schenone A; Faber CG; Mazzeo A; Grisold W; Valsecchi M; Cavaletti G;
Neurology; 2021 Aug; 97(7):e660-e672. PubMed ID: 34078718
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy-induced peripheral neuropathy-patient-reported outcomes compared with NCI-CTCAE grade.
Tan AC; McCrary JM; Park SB; Trinh T; Goldstein D
Support Care Cancer; 2019 Dec; 27(12):4771-4777. PubMed ID: 30972648
[TBL] [Abstract][Full Text] [Related]
19. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).
Schloss JM; Colosimo M; Airey C; Masci P; Linnane AW; Vitetta L
Support Care Cancer; 2017 Jan; 25(1):195-204. PubMed ID: 27612466
[TBL] [Abstract][Full Text] [Related]
20. Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial.
Shimozuma K; Ohashi Y; Takeuchi A; Aranishi T; Morita S; Kuroi K; Ohsumi S; Makino H; Katsumata N; Kuranami M; Suemasu K; Watanabe T; Hausheer FH
Support Care Cancer; 2012 Dec; 20(12):3355-64. PubMed ID: 22584733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
